Drug-coating Balloon Treatment in Coronary Artery Disease

NCT04255563 · tracked via the Priya Life Science China tracker

Sponsor

Nanjing First Hospital, Nanjing Medical University

Phase

Observational

Started

2020-02-25

Last updated

2024-11-15

Condition(s) studied

Coronary Artery Disease

Investigational drug(s) / intervention(s)

DCB treatment

DCB treatment: DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.

Study summary

Drug-coated balloon (DCB) is an alternative choice for patients with coronary artery disease (CAD). This study is to investigate the efficacy and safety of DCB treatment in patients with CAD.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients suitable for DCB treatment Exclusion Criteria: * Pregnancy * Contraindications to contrast media, antiplatelet therapy, or paclitaxel * Expected life less than 12 months * Cardiac shock

Primary outcome measure(s)

target vessel failure (TVF) at 12 months — 12 months
TVF is defined as the composite of cardiac death, target-vessel myocardial infarction and ischemia-driven target- vessel revascularization.

Trial sites (1)

Facility	City	Region	Status
Nanjing First Hospital	Nanjing	Jiangsu	Recruiting

More Nanjing First Hospital, Nanjing Medical University trials in China

Predictors and Clinical Outcomes of Patients With Coronary Heart Disease Co-morbid Depression Post Percutaneous Coronary Intervention Active, not recruiting

Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome Recruiting

The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM). Starting soon

National Registry and Cohort Study of Pulmonary Vascular Disease Recruiting

Application of CLCVP Technique in Early Intervention of CSA-AKI Recruiting

Other trials for the same condition

No-Touch Versus Conventional Saphenous Vein Harvesting Technique Active, not recruiting

CRUSTAL Study in China Active, not recruiting

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome Recruiting

A Prospective Multicenter Real-World Registry of Quantitative Flow Ratio-Guided Coronary REvascularization and QuAlity evaLuation Starting soon

NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04255563 on ClinicalTrials.gov ↗ ← All trials in China